Sellas Life Sciences is trading at $10.60 (+5.9%) as the stock continues its recent upward trajectory fueled by positive clinical and funding narratives.
- Investor sentiment remains high due to optimism surrounding the company's late-stage REGAL trial and reports of strong institutional buying.
- While there is no fresh stock-specific news today, the move aligns with a broader risk-on tone across the equity markets.
- The stock continues to benefit from sustained momentum following a period of sharp gains and improved funding outlooks.